Tag Archives: June

Breyanzi Starts EMA Assessment in 2L LBCL (TI); Tecartus and Yescarta Absent from June’s CHMP Agenda

On Monday, June 20, the CHMP agenda for June was released. Of note, Breyanzi (BMS’s CD19 CAR-T) was listed as ‘Start of Procedure’ under ‘Type II Variations: Extension of Indications’ for 2L LBCL transplant-intended (TI) patients. Additionally, Tecartus (Gilead / Kite’s CD19 CAR-T) in r/r adult B-ALL and Yescarta (Gilead / Kite’s CD19 CAR-T) for 2L LBCL were absent from the CHMP agenda.

About The Author

The Celltelligence Team

Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.


You’ll be able to access the full article from your Celltelligence Library after signing up.